Welcome!

News Feed Item

Status Epilepticus Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Status Epilepticus Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html

Status Epilepticus Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Status Epilepticus Global Clinical Trials Review, H2, 2014" provides data on the Status Epilepticus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Status Epilepticus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Status Epilepticus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Status Epilepticus 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Status Epilepticus 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Status Epilepticus Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Sage Therapeutics 30
Clinical Trial Overview of Sage Therapeutics 30
Ligand Pharmaceuticals, Inc. 31
Clinical Trial Overview of Ligand Pharmaceuticals, Inc. 31
Mylan Inc. 32
Clinical Trial Overview of Mylan Inc. 32
Clinical Trial Overview of Top Institutes / Government 33
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Xuanwu Hospital Capital Medical University 35
Clinical Trial Overview of Xuanwu Hospital Capital Medical University 35
University of Malawi 36
Clinical Trial Overview of University of Malawi 36
Postgraduate Institute of Medical Education and Research 37
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 37
Shiraz University of Medical Sciences 38
Clinical Trial Overview of Shiraz University of Medical Sciences 38
University of Virginia 39
Clinical Trial Overview of University of Virginia 39
Hillel Yaffe Medical Center 40
Clinical Trial Overview of Hillel Yaffe Medical Center 40
All India Institute of Medical Sciences 41
Clinical Trial Overview of All India Institute of Medical Sciences 41
University of Michigan 42
Clinical Trial Overview of University of Michigan 42
Five Key Clinical Profiles 43
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 69

List of Tables

Status Epilepticus Therapeutics, Global, Clinical Trials by Region, 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Status Epilepticus Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Sage Therapeutics, 2014* 30
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Ligand Pharmaceuticals, Inc., 2014* 31
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Mylan Inc., 2014* 32
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 34
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Xuanwu Hospital Capital Medical University, 2014* 35
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malawi, 2014* 36
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 37
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2014* 38
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Virginia, 2014* 39
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Hillel Yaffe Medical Center, 2014* 40
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 41
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 42

List of Figures

Status Epilepticus Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 68


To order this report: Status Epilepticus Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, will go over the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, applicatio...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Microsoft Azure Container Services can be used for container deployment in a variety of ways including support for Orchestrators like Kubernetes, Docker Swarm and Mesos. However, the abstraction for app development that support application self-healing, scaling and so on may not be at the right level. Helm and Draft makes this a lot easier. In this primarily demo-driven session at @DevOpsSummit at 21st Cloud Expo, Raghavan "Rags" Srinivas, a Cloud Solutions Architect/Evangelist at Microsoft, wi...
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...